Triweekly XELOX Versus Single Capecitabine Concomitant with Neoadjuvant Radiotherapy for Locally Advanced Rectal Cancer
Metrics
Topics
Related Documents
Neoadjuvant capecitabine and oxaliplatin (XELOX) with bevacizumab for locally advanced rectal cancer.
Junichi HasegawaTsunekazu MizushimaHo Min KimYasuhiro MiyakeHiroyoshi TakemotoHiroshi TamagawaShingo NouraMasayuki OhueMakoto FujiiYuichiro FujieHirofumi OtaTakeshi KatoMutsumi FukunagaIchiro TakemasaMasataka IkedaHirofumi YamamotoM SekimotoRiichiro NezuYuichiro� DokiMasaki Mori
Neoadjuvant XELOX vs. XELIRI in combination with concomitant boost 3D-conformal radiotherapy in locally advanced rectal cancer (LARC)
Giuseppe PriviteraCorrado SpatolaGrazia AcquavivaGregorio Di FrancoL. RaffaeleVincenzo SalamoneGiovanni Carlo Ettorre
Neoadjuvant Capecitabine Combined with Standard Radiotherapy in Patients with Locally Advanced Rectal Cancer
Juergen DunstJürgen DebusVolker RudatJoern WulfWilfried BudachTobias HoelscherThomas S. ReeseStephan MoseClaus RöedelHelmut ZuehlkeAxel Hinke
Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer
Jinghua TangXiaojun WuYanfang BaiYuanhong GaoJiang WuLing-Heng KongJunzhong LinDesen WanZhizhong PanPeirong Ding
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer
Giampietro GaspariniFrancesco TorinoTakayuki UenoStefano CascinuTeresa TroianiAlberto BallestreroRossana BerardiJunichi ShishidoAkihiko YoshizawaYukiko MoriSatoshi NagayamaPaola MorosiniMasakazu Toi